Request Demo

Last update 23 Jan 2025

SRF

Last update 23 Jan 2025

Basic Info

Synonyms

MCM1, serum response factor, SRF

Introduction

SRF is a transcription factor that binds to the serum response element (SRE), a short sequence of dyad symmetry located 300 bp to the 5' of the site of transcription initiation of some genes (such as FOS). Together with MRTFA transcription coactivator, controls expression of genes regulating the cytoskeleton during development, morphogenesis and cell migration. The SRF-MRTFA complex activity responds to Rho GTPase-induced changes in cellular globular actin (G-actin) concentration, thereby coupling cytoskeletal gene expression to cytoskeletal dynamics. Required for cardiac differentiation and maturation.

Drugs associated with SRF

CCG-232964

Target

MRTFB x RP4 x SRF

Mechanism

MRTFB inhibitors [+2]

Active Org.

University of Michigan

Originator Org.

University of Michigan

Active Indication

Scleroderma, Systemic

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

CCG-203971

Target

MRTFA x SRF

Mechanism

MRTFA inhibitors [+1]

Active Org.

Genesis Biosciences LLC [+3]

Originator Org.

Genesis Biosciences LLC

Active Indication

Glaucoma, Open-Angle [+1]

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with SRF

100 Translational Medicine associated with SRF

0 Patents (Medical) associated with SRF

3,709

Literatures (Medical) associated with SRF

01 Mar 2025·American Journal of Ophthalmology

Combining Paracentral Acute Middle Maculopathy and Peripapillary Fluid as Biomarkers in Anterior Ischemic Optic Neuropathy

Article

Author: Heegaard, Steffen ; Fana, Viktoria ; Subhi, Yousif ; Lykkebirk, Lea ; Døhn, Uffe Møller ; Terslev, Lene ; Brittain, Jane Maestri ; Klefter, Oliver Niels ; Hansen, Michael Stormly ; Wiencke, Anne Katrine ; Jensen, Mads Radmer ; Hamann, Steffen

PURPOSETo determine if paracentral acute middle maculopathy (PAMM) and peripapillary intraretinal and subretinal fluid (IRF/SRF) could help distinguish between arteritic anterior ischemic optic neuropathy (A-AION) and nonarteritic AION (NA-AION) at an early stage.DESIGNNested prospective cross-sectional diagnostic accuracy study.METHODSThis study used single-center optical coherence tomography (OCT) data from 8 patients with A-AION and 24 patients with NA-AION from two prospective cross-sectional studies with consecutive sampling (ClinicalTrials.gov: NCT05248906 and NCT05305079). The diagnosis of A-AION was based on expert interpretation of biochemical markers of inflammation, temporal artery biopsy and positron emission tomography/computed tomography. The diagnosis of NA-AION was made in cases without suspicion or clinical evidence of A-AION and with confirmed neuroophthalmological expert diagnosis. For this substudy patients were also required to have an OCT scan in relation to the diagnosis of AION. Macular OCT scans were graded by two independent, masked graders for the presence of PAMM and for IRF/SRF. The extension of IRF/SRF was assessed using an Early Treatment Diabetic Retinopathy Study (ETDRS) grid.RESULTSPAMM was found in 50% of patients with A-AION and in 0% of patients with NA-AION (P = .0019). In the setting of AION, the sensitivity of PAMM for the diagnosis of A-AION was 50% (95% CI: 16%-84%) while the specificity was 100% (95% CI: 86%-100%). Conversely, peripapillary IRF/SRF with extension into the ETDRS grid was observed in 83% of patients with NA-AION but in 0% of patients with A-AION (P = .000047). The sensitivity of central macula-involving IRF/SRF for the diagnosis of NA-AION was 83% (95% CI: 63%-95%), while the specificity was 100% (95% CI: 63%-100%). Combining the two biomarkers, 75% of patients with AION could be classified based on OCT alone.CONCLUSIONPAMM appears to be a biomarker of A-AION while extensive peripapillary fluid appears to be a biomarker of NA-AION. Combining OCT biomarkers might allow for early classification of AION and warrants further prospective studies.

01 Mar 2025·Journal Français d'Ophtalmologie

Subthreshold nanosecond laser therapy for chronic central serous chorioretinopathy: A prospective study

Article

Author: Aljundi, W ; Munteanu, C ; Hartmann, M ; Kaymak, H ; Seitz, B ; Fraenkel, D ; Abdin, A D

PURPOSETo investigate the morphologic and functional outcomes of nanosecond subthreshold (ST) laser treatment for patients with chronic central serous chorioretinopathy (CSC).METHODSIn this prospective study, 44 patients were treated with the ST nanosecond laser with a follow-up period of 12 months. All target variables were measured at 1, 3, 6 and 12 months after the first laser treatment.RESULTSThis study showed a significant improvement in macular sensitivity (MS), a significant reduction in central macular thickness (CMT) as well as a significant reduction in subretinal fluid height (SRF) after 3 months of treatment. The subfoveal choroidal thickness (SFCT) was significantly reduced after 12 months of treatment. However, the best-corrected visual acuity (BCVA) (logMAR) did not change significantly at any time during the study. A high proportion of patients (85%) showed complete resolution of SRF after 12 months, indicating a positive response to treatment in the majority of our patients.CONCLUSIONThis study showed statistically significant functional improvement in MS as well as significant anatomical reduction in CMT, SFCT and SRF height in CSC patients treated with ST nanosecond laser therapy. Patients with higher SRF at baseline required repeated laser treatments to achieve complete resolution of the SRF.

01 Mar 2025·Brain, Behavior, and Immunity

The intersection of endocrine signaling and neuroimmune communication regulates muscle inflammation-induced nociception in neonatal mice

Article

Author: Gupta, Prakriti ; Jankowski, Michael P ; Raut, Namrata G R ; Dourson, Adam J ; Fadaka, Adewale O ; Hofmann, Megan C

Neonatal pain is a significant clinical issue but the mechanisms by which pain is produced early in life are poorly understood. Our recent work has linked the transcription factor serum response factor downstream of local growth hormone (GH) signaling to incision-related hypersensitivity in neonates. However, it remains unclear if similar mechanisms contribute to inflammatory pain in neonates. We found that local GH treatment inhibited neonatal inflammatory myalgia but appeared to do so through a unique signal transducer and activator of transcription (STAT) dependent pathway within sensory neurons. The STAT1 transcription factor appeared to regulate peripheral inflammation itself by modulation of monocyte chemoattractant protein 1/C-C motif chemokine ligand 2 (MCP1/CCL2) release from sensory neurons. Data suggests that STAT1 upregulation, downstream of GH signaling, contributes to neonatal nociception during muscle inflammation through a novel neuroimmune loop involving chemokine release from primary afferents. Results could uncover new ways to treat muscle pain and inflammation in neonates.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

SRF

Basic Info

Related

Analysis